Table of Content

Introduction
Executive Summary
PI3K inhibitors: Overview
• Classification
• Mechanism of Action
• Structure
• Application
Pipeline Therapeutics
• Comparative Analysis
Therapeutic Assessment
• Assessment by Product Type
• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type
PI3K inhibitors – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
• PI3K inhibitors companies’ collaborations, Licensing, Acquisition -Deal Value Trends
PI3K inhibitors Collaboration Deals
• Company-Company Collaborations (Licensing / Partnering) Analysis
• Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
• Comparative Analysis
Umbralisib: TG Therapeutics
• Product Description
• Research and Development
• Product Development Activities
Mid Stage Products (Phase II)
• Comparative Analysis
Gedatolisib: Pfizer
• Product Description
• Research and Development
• Product Development Activities
Parsaclisib: Incyte Corporation
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report?..
Early Stage Products (Phase I)
• Comparative Analysis
Drug Name: Company Name
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report?..
Pre-clinical and Discovery Stage Products
• Comparative Analysis
YH 25248: Yuhan
• Product Description
• Research and Development
• Product Development Activities
Inactive Products
• Comparative Analysis
PI3K inhibitors Key Companies
PI3K inhibitors Key Products
PI3K inhibitors- Unmet Needs
PI3K inhibitors- Market Drivers and Barriers
PI3K inhibitors- Future Perspectives and Conclusion
PI3K inhibitors Analyst Views
PI3K inhibitors Key Companies
Appendix



List of Figures


Figure 1 Total Products for PI3K inhibitors
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products


List of Tables


Table 1 Total Products for PI3K inhibitors
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products